The DOI matches its Crossref record.
The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease
Abstract
Treatment of Alzheimer's disease has been dominated by the use of acetylcholinesterase (AChE) inhibitors. These drugs compensate for the death of cholinergic neurons and offer symptomatic relief by inhibiting acetylcholine (ACh) turnover and restoring synaptic levels of this neurotransmitter. Recently, however, AChE itself has been implicated in the pathogenesis of Alzheimer's disease. In particular, it appears that AChE may directly interact with amyloid-beta in a manner that increases the deposition of this peptide into insoluble plaques. This new role suggests that properly designed AChE inhibitors might be able to act as disease-modifying agents rather than as mere palliatives. Additionally, numerous studies have suggested that cholinergic modulation and other functional consequences of AChE inhibition may affect amyloid precursor protein processing and protect neurons against a variety of insults. It therefore seems likely that new AChE inhibitors, which capitalize on all these strengths would be excellent candidates for future Alzheimer's disease therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An increase of acetylcholine concentration (ACh) at the synapse by inhibiting the acetylcholinesterase (AChE) is one of the approaches to slow down the progression of AD [18,19,20,21,22,23,24,25,26].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [19]
Citations
Cited by
Sorted by citations
García‐Ayllón, M. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00022 · Cited by 303
“…al., 1986; Mesulam and Geula, 1990; Massoulié et al., 1993; Layer, 1995; Small et al., 1996; Kása et al., 1997; Grisaru et al., 1999; Talesa, 2001; Rees and Brimijoin, 2003; Ballard et al., 2005; Silman and Sussman, 2005; Frontiers in Molecular Neuroscience www.frontiersin.org September 2011 |…”
BackgroundAlzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R.-N., Bild, V., Chiriac, S. I. B., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 307
“During the enzymatic attack on acetylcholine, which is an ester with trigonal geometry, a tetrahedral intermediate is formed between the enzyme and the substrate [14,30].”
BackgroundA molecular approach in drug development for Alzheimer’s disease
Agatonović-Kuštrin, S., Kettle, C., & Morton, D. W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.147 · Cited by 240
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
“Thus, inhibition of AChE might influence the APP processing and Aβ deposition, leading to the reduction of one of the pathological expressions of the disease [23].”
BackgroundSilva, T., Reis, J., Teixeira, J., & Borges, F. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.008 · Cited by 158
Metadata
- Authors
- Rees, T. M., & Brimijoin, S.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Brimijoin, S.
- Venue
- Drugs of today
- Publisher
- Portico
- Published
- 2003
- Volume
- 39
- Issue
- 1
- Pages
- 75
- ISSN
- 0025-7656 (ISSN-L)
- 1699-4019
- OpenAlex
- W1966053837
- Cited by
- 171
- References
- 0
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 25 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs of today (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG 16574, P50AG016574)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- acetylcholinesterase, Alzheimer's disease pathogenesis, acetylcholinesterase inhibitors, amyloid-beta deposition, amyloid plaques, cholinergic neurons, APP processing, disease-modifying therapy, acetylcholine neurotransmission
- MeSH terms
- Acetylcholinesterase, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
